A matching-adjusted indirect comparison of centanafadine versus lisdexamfetamine, methylphenidate and atomoxetine in adults with attention-deficit/hyperactivity disorder: long-term safety and efficacy
Journal of Comparative Effectiveness Research · 2024
DOI: 10.57264/cer-2024-0089 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Comparative Effectiveness Research, 2024. Verfasst von Jeff Schein und 7 weiteren Autor:innen. Beteiligte Einrichtung: Otsuka Pharmaceutical Development & Commercialization, Inc., 508 Carnegie Center, Princeton, NJ 08540, USA. Hauptthemen laut MEDLINE: Attention Deficit Disorder with Hyperactivity, Atomoxetine Hydrochloride, Lisdexamfetamine Dimesylate, Methylphenidate. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Aim
To compare long-term safety and efficacy outcomes of centanafadine versus lisdexamfetamine dimesylate (lisdexamfetamine), methylphenidate hydrochloride (methylphenidate) and atomoxetine hydrochloride (atomoxetine), respectively, in adults with attention-deficit/hyperactivity disorder (ADHD) using matching-adjusted indirect comparisons (MAICs). Patients & methods: Patient-level data from a centanafadine trial (NCT03605849) and published aggregate data from a lisdexamfetamine trial (NCT00337285), a methylphenidate trial (NCT00326300) and an atomoxetine trial (NCT00190736) were used. Patient characteristics were matched in each comparison using propensity score weighting. Study outcomes were assessed up to 52 weeks and included safety (rates of adverse events [AEs]) and efficacy (mean change from baseline in the Adult ADHD Investigator Symptom Rating Scale [AISRS] or ADHD Rating Scale [ADHD-RS] score).
Results
In all comparisons of matched populations, risks of AEs were statistically significantly lower with centanafadine or non-different between centanafadine and comparator; the largest differences in AE rates included upper respiratory tract infection (risk difference in percentage points: 18.75), insomnia (12.47) and dry mouth (12.33) versus lisdexamfetamine; decreased appetite (20.25), headache (18.53) and insomnia (12.65) versus methylphenidate; and nausea (26.18), dry mouth (25.07) and fatigue (13.95) versus atomoxetine (all p < 0.05). Centanafadine had a smaller reduction in the AISRS/ADHD-RS score versus lisdexamfetamine (6.15-point difference; p < 0.05) and no statistically significant difference in the change in AISRS score versus methylphenidate (1.75-point difference; p = 0.13) and versus atomoxetine (1.60-point difference; p = 0.21).
Conclusion
At up to 52 weeks, centanafadine showed significantly lower incidence of several AEs than lisdexamfetamine, methylphenidate and atomoxetine; efficacy was lower than lisdexamfetamine and non-different from methylphenidate and atomoxetine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Otsuka Pharmaceutical Development & Commercialization, Inc., 508 Carnegie Center, Princeton, NJ 08540, USA.
- Analysis Group, Inc., 1190 avenue des Canadiens-de-Montréal, Tour Deloitte, Suite 1500, Montréal, QC, H3B 0G7, Canada.
- Analysis Group, Inc., 151 West 42nd Street, 23rd Floor, New York, NY 10036, USA.
- Center for Psychiatry & Behavioral Medicine, 7351 Prairie Falcon Rd STE 160, Las Vegas, NV 89128, USA.
ORCID-Profile: Martin Cloutier, Marjolaine Gauthier-Loiselle, Maryaline Catillon
Zitieren
APA
Schein, J., Cloutier, M., Gauthier-Loiselle, M., Catillon, M., Xu, C., Qu, A., Lee, F., & Childress, A. (2024). A matching-adjusted indirect comparison of centanafadine versus lisdexamfetamine, methylphenidate and atomoxetine in adults with attention-deficit/hyperactivity disorder: long-term safety and efficacy. Journal of Comparative Effectiveness Research. https://doi.org/10.57264/cer-2024-0089
Vancouver
Schein J, Cloutier M, Gauthier-Loiselle M, Catillon M, Xu C, Qu A, et al. A matching-adjusted indirect comparison of centanafadine versus lisdexamfetamine, methylphenidate and atomoxetine in adults with attention-deficit/hyperactivity disorder: long-term safety and efficacy. Journal of Comparative Effectiveness Research. 2024. doi:10.57264/cer-2024-0089
BibTeX
@article{Schein2024,
author = {Schein, Jeff and Cloutier, Martin and Gauthier-Loiselle, Marjolaine and Catillon, Maryaline and Xu, Chunyi and Qu, Alice and Lee, Francesca and Childress, Ann},
title = {A matching-adjusted indirect comparison of centanafadine versus lisdexamfetamine, methylphenidate and atomoxetine in adults with attention-deficit/hyperactivity disorder: long-term safety and efficacy},
journal = {Journal of Comparative Effectiveness Research},
year = {2024},
doi = {10.57264/cer-2024-0089}
}
EUVIMED